BofA lowered the firm’s price target on Nevro to $4 from $14 on Friday, citing declining revenue. The firm keeps an Underperform rating on the shares after the company missed Q2 revenue and lowered its 2024 revenue guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: